Navigation Links
New treatment to overpower drug resistance in ovarian cancer
Date:11/15/2010

Drug resistance is a major obstacle in curing ovarian cancer but new research from the Centenary Institute has discovered a treatment that kills ovarian cancer cells in a new way that can break the resistance mechanism. Published today in Autophagy, the researchers found the drug (FTY720) had a potent effect in human ovarian cancer cells, even in those resistant to cisplatin, the most commonly used chemotherapeutic drug currently available for the treatment of ovarian cancer.

Centenary Institute Signal Transduction Head Associate Professor Pu Xia described the findings as a breakthrough in ovarian cancer treatment because, FTY720 kills ovarian cancer cells through a unique way different to the current anti-cancer drugs. Current treatments, such as cisplatin, kill ovarian cancer cells through a way of programming cell death known as apoptosis but this is often reversible or demolished by cancer cells. However, FTY720 kills cells through an irreversible process known as necrosis so the cancer cells cannot resist, repair and relapse.

Each year, around 800 Australian women die from ovarian cancer1, and ovarian cancer remains the leading cause of death in women with gynaecological malignancies over the world.

Dr Xia said: "One of the major reasons for such a poor outcome of ovarian cancer is that the cancer cells have an ability to resist the current chemotherapeutic drugs through a protective shield, which occurs naturally or as a response to the treatment, and this survives the cancer from the treatment. Such a protective shield, uncovered by the findings from the Xia laboratory, is built, at least partially, on a catabolic process, called autophagy, by which cells eat their own non-vital components for survival under stress conditions such as starvation or chemotherapy. Remarkably, despite this survival process being activated by ovarian cancer cells during the treatment, FTY720 is still capable of killing them effectively.

While this research is a major first step toward developing a more effective treatment for ovarian cancer, the researchers claim more pre-clinical and clinical trials are needed before the drug might be used in women with ovarian cancer. However, the researchers are optimistic that the treatment would be available as a new chemotherapeutic agent within the next several years, because this drug has been approved by the US Food and Drug Administration (FDA) for use in the treatment of multiple sclerosis and is also used in multiple clinical trials for the prevention of organ transplant rejection and the treatment of various autoimmune diseases. Recent studies have also shown anti-tumour efficacy in several types of cancers but this is the first time it has been studied for the treatment of ovarian cancer.


'/>"/>

Contact: Tanya Sarina
t.sarina@centenary.org.au
61-295-656-228
Centenary Institute
Source:Eurekalert

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. The dietary supplement genistein can undermine breast cancer treatment
3. Coming soon: Self-guided, computer-based depression treatment
4. Nanodiamond drug device could transform cancer treatment
5. Disinfectants can make bacteria resistant to treatment
6. Scientists from Granada find a potential treatment to prevent diabetes and obesity
7. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
8. Researchers at National Jewish Health evaluating a treatment
9. National Jewish Health researchers evaluating treatment to help emphysema sufferers breathe easier
10. First comprehensive genomic study of common cold reveals new treatment targets
11. Iowa State researcher develops new treatment method for canine eye diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... 23, 2017  Hunova, the first robotic gym for the rehabilitation and ... launched in Genoa, Italy . The first 30 robots ... the USA . The technology was developed and patented ... the IIT spin-off Movendo Technology thanks to a 10 million euro investment ... please click: ...
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... today it will be hosting a Webinar titled, “Pathology is going digital. Is ... , on digital pathology adoption best practices and how Proscia improves lab economics ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
(Date:10/10/2017)... ... ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled a ... new look is part of a transformation to increase awareness, appeal to new markets ... It will also expand its service offering from its signature gourmet cooking classes and ...
Breaking Biology Technology: